<DOC>
	<DOC>NCT00601770</DOC>
	<brief_summary>The objective is to investigate the virological (HCV-RNA) responses following biweekly immunization with IC41. Treatment phase 14 weeks, total study duration including follow-up period 38 weeks.</brief_summary>
	<brief_title>Virological Response Study of the HCV Vaccine IC41</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>Written informed consent obtained prior to study entry Patients with chronic hepatitis C; genotype 1 Treatment naive patients Male and Female, 18 to 55 years Presence of HLAA2 marker Mentally healthy No clinically relevant pathological findings in any of the investigations at screening Treatment naive patients with chronic Hepatitis C of genotype 1 Positive results in HIV, HBsAg and HAVAg (IgM) Other causes of chronic hepatitis History of autoimmune diseases Previous vaccination with any prophylactic or therapeutic Hepatitis C vaccine (in a clinical study) Active or passive vaccination 4 weeks before and during the entire study period Decompensated liver disease History of severe hypersensitivity reactions and anaphylaxis Known allergic reactions to one of the components of the vaccine and Imiquimod cream Clinically significant diseases which, in the opinion of the Investigator, might lead to frequent hospitalization/medical attendance Malignancies Immunosuppressive therapy Pregnancy, lactation or breastfeeding Unwillingness to practice appropriate contraception Participation in another study with an investigational drug within 1 month prior to enrolment and the entire study period Patients, who in the opinion of the Investigator, might not be able to comply with the study protocol (e.g.: Drug addiction, alcoholism)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>